Use of GLP-1s, especially semaglutide and liraglutide, may increase risk for nonarteritic anterior ischemic optic neuropathy ...

A recent study shows the use of GLP-1 drugs can increase the risk for optic nerve damage in the first year of treatment, ...

Twenty years ago, Roger Cone, Ph.D. made a key discovery in obesity science which could help Courage Therapeutics deliver ...

GLP-1 receptor agonists are an important drug class and have become widely popular due to their effectiveness in weight ...

A small study of Sanofi’s lixisenatide has suggested that the GLP-1 agonist could slow down the progression of Parkinson’s disease.

The race for obesity drug assets is becoming more intense as pharmaceutical companies strive to develop effective treatments for weight loss. This article explores the efficacy, potential sales ...

This is a detailed, evidence-based review of the most popular weight loss medications on the market today.

Researchers at Osaka University, Japan have reported a genome editing strategy that allowed mice to produce their own weight ...

There's been plenty of buzz about this class of drug, following publication of a high-profile trial this year. How much do we ...